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ABSTRACT 40 
 41 
Purpose: To investigate the effects of mild-to-moderate cystic fibrosis (CF) on the 42 
pulmonary oxygen uptake (V̇O2) kinetics of 7 pediatric patients (13.5 ± 2.8 y) versus 7 43 
healthy matched controls (CON; 13.6 ± 2.4 y). We hypothesized that CF would slow the V̇O2 44 
kinetic response at the onset of moderate (MOD) and very heavy (VH) intensity cycling. 45 
Methods: Changes in breath-by-breath V̇O2, near-infrared spectroscopy-derived muscle 46 
deoxygenation ([HHb]) at the m. vastus lateralis and thoracic bioelectrical impedance-47 
derived heart rate, stroke volume index (SVI) and cardiac index (CI) were measured during 48 
repeat transitions to MOD (90% of the gas exchange threshold) and VH (Δ60%) intensity 49 
cycling exercise. Results: During MOD, the phase II V̇O2 τ (p=0.84; effect size (ES) = 0.11) 50 
and overall mean response time (MRT) (p=0.52; ES=0.11) were not significantly slower in 51 
CF versus CON. However, during VH exercise, the phase II V̇O2 τ (p=0.02, ES=1.28) and 52 
MRT (p=0.01, ES=1.40) were significantly slower in CF. Cardiac function, central O2 53 
delivery (SVI and CI) and muscle [HHb] kinetics were unaltered in CF. However, the 54 
arterial-venous O2 content difference (C(a-v̅)O2) was reduced (p=0.03) during VH at 30 s, with 55 
a trend for reduced levels at 0 s (p=0.07), 60 s (p=0.05) and 120 s (p=0.07) in CF. 56 
Furthermore, ∆C(a-v̅)O2 significantly correlated with the VH phase II V̇O2 τ (r= -0.85; p=0.02) 57 
and MRT (r = -0.79; p=0.03) in CF only. Conclusion: Impairments in muscle oxidative 58 
metabolism during constant work rate exercise are intensity-dependent in young people with 59 
mild-to-moderate CF. Specifically, V̇O2 kinetics are slowed during VH but not MOD cycling 60 
and appear to be mechanistically linked to impaired muscle O2 extraction and utilization.  61 
 62 
Keywords: oxidative muscle metabolism; pulmonary disease; near-infrared spectroscopy; 63 
oxygen delivery; pediatrics.  64 
 65 
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INTRODUCTION 66 
 67 
Maximal O2 uptake (V̇O2max) is clinically important in patients with cystic fibrosis (CF), 68 
given associations with prognosis (26), risk of hospitalization (25) and health-related quality 69 
of life (11). V̇O2max by definition does not, however, represent the rate at which aerobic 70 
energy transfer adapts to the changing metabolic demands facing O2 transport and utilization 71 
during everyday life. In contrast, assessing the dynamic adjustment in pulmonary V̇O2 [time 72 
constant (τ) for the primary component (phase II)] at the onset of exercise provides a non-73 
invasive insight into muscle O2 consumption dynamics (21) and the breakdown of muscle 74 
phosphocreatine (PCr) (30, 4). Consequently, this parameter can provide insight into the 75 
factor(s) mediating muscle metabolic function and the integration of the respiratory, 76 
cardiovascular and muscular systems can also be characterized. Although the V̇O2 kinetic 77 
response and mechanism(s) regulating the rate of rise are relatively well documented in 78 
healthy children (for a review see (2)), there is limited evidence in young people with CF. 79 
 80 
Slower V̇O2 kinetics have been reported in people with CF during incremental (33, 17), 81 
pseudo-random binary sequence (PRBS) (22) and constant work rate (CWR) exercise (19, 1). 82 
However, a similar response to healthy controls (11-15 years) has also been documented 83 
during intense exercise (7). Methodological issues may explain these disparities. Firstly, 84 
during incremental and PRBS exercise the phase II portion of the V̇O2 response was not 85 
isolated, which is critical to reflect the kinetics of muscle O2 consumption (21). Secondly, the 86 
CWR exercise study by Hebestreit and colleagues (19) did not prescribe work rate within 87 
physiologically defined exercise intensity domains. Furthermore, semi-recumbent cycling 88 
was used which may negate muscle O2 delivery during exercise, and a mixed age group of 89 
10-33 years, which would comprise a range of pulmonary function characteristics, were 90 
tested (19).  91 
4 
  
According to the Fick principle, the rate of adjustment in V̇O2 is dictated by O2 delivery and 92 
utilization mechanisms. Although the Fick equation has been used to provide mechanistic 93 
interpretation during incremental exhaustive exercise in CF (33), few studies have applied 94 
this to understand how CF modifies the V̇O2 kinetic response to CWR exercise (41). Slower 95 
V̇O2 kinetics in CF have been linked to inadequate O2 delivery (19), inferred from arterial O2 96 
saturation (SpO2%). Although children with CF may present with early signs of 97 
cardiovascular abnormalities (18, 38, 28), impaired skeletal muscle oxidative capacity in CF 98 
is reported (29, 33, 39, 15, 12). However, contrasting data has reported no differences in 99 
skeletal muscle oxidative function in young people with CF compared with their healthy 100 
peers (40). The near-infrared spectroscopy (NIRS)-derived muscle deoxygenation (∆[HHb]) 101 
signal provides insight into the ratio of local muscle O2 delivery to muscle O2 utilization. 102 
Thus, changes in muscle HHb are considered to represent changes in muscle O2 extraction 103 
dynamics during exercise (e.g. 16). Although it has been hypothesised that more rapid muscle 104 
HHb dynamics would be evident in the face of reduced central or muscle O2 delivery (16), 105 
children and adolescents with CF do not appear able to compensate in this manner during 106 
incremental exercise (29, 33). This raises questions regarding the capacity of CF skeletal 107 
muscle to increase muscle O2 extraction during exercise, but this has yet to be evaluated 108 
alongside V̇O2 kinetics during CWR cycling exercise.  109 
 110 
Consequently, this study aimed to characterize the pulmonary V̇O2 kinetic response of 111 
children and adolescents with mild-to-moderate CF at the onset of moderate (MOD) and very 112 
heavy (VH) intensity cycling exercise. It was hypothesized that: 1) a longer phase II V̇O2 τ at 113 
the onset of MOD and VH exercise would be evident in CF; 2) slower cardiac output (?̇?) 114 
(inferred from the CI) and more rapid [HHb] kinetics would be evident in CF during MOD 115 
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and VH exercise; and 3) slower V̇O2 kinetics would relate to reduced ?̇? and altered muscle 116 
∆[HHb] dynamics in the CF group.  117 
 118 
MATERIALS AND METHODS 119 
Study Participants. Seven young people with stable, mild-to-moderate CF (Tables 1 and 2) 120 
and 7 controls (CON) (Table 2) participated. Inclusion and exclusion criteria are detailed 121 
elsewhere (31, 32). Neither group presented with contraindications to exercise. Ethics 122 
approval was granted by the South West NHS Research Ethics Committee. Informed written 123 
consent was obtained from parent(s)/guardian(s) and participants.  124 
 125 
[Insert Tables 1 and 2 here] 126 
 127 
Experimental protocol 128 
Participants attended the laboratory five times over a two week period, at a similar time of 129 
day and separated by 24-48 h. Participants were advised to arrive rested and hydrated, > 2 h 130 
postprandial and having refrained from caffeine (> 2 h). All exercise was performed on a 131 
cycle ergometer (Lode, Groningen, The Netherlands or Lode Corival (Pediatric), Groningen).  132 
 133 
Visit 1: CPET protocol. Following anthropometric and pulmonary function measurements, a 134 
combined ramp incremental and supramaximal (Smax) CPET was used to determine V̇O2max 135 
and the gas exchange threshold (GET) (31, 32). Briefly, this protocol involved an exhaustive 136 
ramp incremental (10-25 W·min
-1
) cycling test with a subsequent Smax (110% peak power 137 
output (PPO)) test to exhaustion, to confirm a valid V̇O2max measurement. Following a 3 min 138 
warm-up (20 W), participants completed the incremental test to the point of volitional 139 
exhaustion, maintaining a cadence of 70-80 rpm throughout. Exhaustion was defined as a ≥10 140 
rpm drop in cadence for 5 consecutive seconds, despite strong verbal encouragement. Active 141 
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(5 min cycling at 20 W) and then passive seated recovery (10 min) then preceded the Smax 142 
test. Smax verification consisted of a 3 min warm-up (20 W), followed by a ‘step’ transition to 143 
a CWR corresponding to 110% PPO. Upon volitional exhaustion (defined above), a 5 min 144 
active recovery (slow cycling at 20 W) concluded the combined CPET session.  145 
 146 
Visits 2-5: CWR exercise. Participants completed MOD and VH CWR exercise tests, 147 
comprising 6 min unloaded pedalling (10 W), followed by transitions to elicit V̇O2 amplitudes 148 
corresponding to 90% GET and Δ60% (60% of the difference between the GET and V̇O2max) 149 
for 6 min. Each set of MOD and VH transitions was performed on separate days, separated 150 
by ≥ 48 h and within a 2 week period. This equated to MOD work rates of 58 ± 24 W and 73 151 
± 35 W for CF and CON, respectively. During VH, CF and CON cycled at 121 ± 43 W and 152 
150 ± 64 W, respectively. Thirty minutes rest separated the MOD and VH transitions.  153 
 154 
Experimental measures 155 
Anthropometry and pulmonary function. Body mass (Seca 220; Vogel & Halke, 156 
Hamburg, Germany) and stature (Seca 220; Vogel & Halke, Hamburg, Germany) were 157 
measured to the nearest 0.01 kg and 0.01 m. Skinfold measurements (Harpenden; British 158 
Indicators, Burgess Hill, UK) were used to estimate percentage body fat (36). Forced vital 159 
capacity (FVC) and forced expiratory volume in 1 s (FEV1) were assessed using spirometry 160 
(Micromedical Microloop 3535, Numed, Sheffield, UK), and expressed as a percentage 161 
predicted using appropriate reference values (37).  162 
 163 
Gas exchange and pulse oximetry. Breath-by-breath changes in gas exchange and 164 
ventilation were determined using a metabolic cart (Metalyzer 3B Cortex, Biophysik, 165 
Leipzig, Germany), which was calibrated each test using gases of known concentration and a 166 
3 L syringe (Hans Rudolph, Kansas City, MO). Fingertip SpO2% was measured on a beat-by-167 
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beat basis at the fingertip using pulse oximetry (NONIN, Avant 4000, NONIN Medical Inc., 168 
USA). 169 
 170 
Near-infrared spectroscopy. A near-infrared spectrometer (Portamon, Artinis Medical 171 
Systems) was used to non-invasively measure [HHb] at the m. vastus lateralis. Details 172 
regarding this system have been outlined previously in an article in this journal concerning 173 
the response of young people with CF during ramp incremental exercise (33). Following 174 
cleaning and shaving of the area of interrogation, the wireless emitter-detector unit was 175 
placed over the muscle belly, midway between the greater trochanter and lateral epicondyle 176 
of the femur. After marking of the placement area, the device was secured with tape 177 
(KinesioTex) and a dark elastic bandage to minimize extraneous light interference with the 178 
near-infrared signal. 179 
 180 
Thoracic Impedance. Beat-by-beat changes in heart rate (HR), SV and ?̇? were measured 181 
using a bioelectrical impedance cardiography system (PhysioFlow, PF-05, Manatec 182 
Biomedical, Paris, France) that has previously been used in CF (e.g. 2).  183 
 184 
CPET parameters of aerobic function. The highest 15 s averaged V̇O2 from the ramp and 185 
Smax tests represented V̇O2max (31) and was normalized to fat-free mass (FFM) using the ratio 186 
standard method. The GET was identified using the V-slope method (5) and confirmed 187 
through visual inspection of the ventilatory equivalents for V̇O2 and V̇CO2.  188 
 189 
Pulmonary ?̇?O2 kinetics. Breath-by-breath changes in V̇O2 were analysed using 190 
methodology previously described by our laboratory (3, 8). Briefly, the four repeat transitions 191 
for both MOD and VH were linearly interpolated to 1 s, time aligned to exercise onset 192 
(i.e., t = 0 s) and ensemble averaged. The 1 s averaged V̇O2 response for the MOD and VH 193 
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conditions for each participant were then baseline corrected, by subtracting the mean 194 
V̇O2 between -60 and -5 s from the exercise response. The duration of phase I was visually 195 
assessed to account for the cardio-dynamic contribution to the V̇O2 kinetic response. The first 196 
21 ± 3 s and 17 ± 4 s of the MOD data and the first 19 ± 5 s and 16 ± 2 s for VH were omitted 197 
in CF and CON participants, respectively. The phase II portion of the V̇O2 response was then 198 
characterised using Equation 1 (GraphPad Prism; GraphPad Software, San Diego, CA): 199 
 200 
V̇O2 (t) = Δ V̇O2 A  · (1 – e 
– (t –TD)/τ
)                          Equation 1.  201 
 202 
 203 
where V̇O2 (t), Δ V̇O2 A, TD, and τ represent the value of V̇O2 at a given time (t), the amplitude 204 
change in V̇O2 from baseline to its asymptote, time delay, and the time constant of the 205 
response, respectively.  206 
 207 
The MRT was derived to describe the overall kinetics during both intensities, by constraining 208 
the TD in Equation 1 to 0 s and fitting from exercise onset to 6 min. The functionalV̇O2 gain 209 
of phase II was determined by dividing the phase II V̇O2 amplitude by the change in work rate 210 
above baseline. End-exercise V̇O2 gain was calculated in a similar manner. For VH exercise, 211 
the V̇O2 slow-component onset and amplitude were determined in line with our previous 212 
work (3, 8). Briefly, Equation 1 was first fit up to the initial 60 s of exercise and then 213 
increased iteratively by 5 s to the end of the exercise bout (LabView, v 6.1, National 214 
Instruments, Newbury, UK). The best fit curve for the phase II portion of the response was 215 
established using: 1) a plot of the V̇O2 τ against time, to identify the point at which the 216 
influence of the V̇O2 slow component lengthened the estimated τ following an initial plateau; 217 
and 2) deviation from an optimal fitting of the model as judged by a systematic departure of 218 
the model’s residuals. The phase II parameter estimates from equation 1 were then resolved 219 
by least-squares non-linear regression (GraphPad Prism, GraphPad Software, San Diego, 220 
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CA). The magnitude of the V̇O2 slow component was calculated as the difference between the 221 
mean of the final 30 s at 6 min of exercise and the phase II asymptote and was expressed in 222 
both absolute terms and relative to end-exercise V̇O2. 223 
 224 
Muscle oxygenation. NIRS data were collected at 10 Hz, interpolated to 1 s intervals and 225 
expressed as a change, in arbitrary units (a.u.), from baseline. Subsequently, [HHb] profiles 226 
were 5 s averaged, time aligned to exercise onset and ensemble averaged to yield a single 227 
response. The dynamics of the primary and slow-component phases of the [HHb] response 228 
were modelled in a similar manner to V̇O2, with slight modification. The exponential-like 229 
increase in [HHb] after the onset of exercise occurred after a discernible delay. The time at 230 
which the exponential-like increase in [HHb] commenced was identified as the point of a 1 231 
SD increase above baseline (3). Equation 1 was then applied to resolve the [HHb] TD and τ 232 
following removal of the data preceding the exponential-like increase. The [HHb] MRT was 233 
calculated by summing TD and τ to provide an overall description of the kinetics in the 234 
primary phase.  235 
 236 
Heart rate, stroke volume, cardiac output and C(a-?̅?)O2. Beat-by-beat changes in HR, SV 237 
and ?̇? were linearly interpolated to 1 s, time aligned and ensemble averaged to 30 s. The 238 
arterial-venous O2 content difference [C(a-v̅)O2] was estimated via rearrangement of the Fick 239 
equation [C(a-v̅)O2 = V̇O2/ ?̇?]. SV and ?̇? were normalized to FFM (12) using the ratio standard 240 
method, to determine the cardiac index (CI) and SV index (SVI). The ?̇?/V̇O2 ratio was used 241 
to provide an index of muscle O2 availability relative to metabolic rate.  242 
  243 
Statistical analyses 244 
Independent samples t-tests examined mean differences between CF and CON. Additionally, 245 
effect size [ES (d)] statistics determined the magnitude of the effect, using a pooled SD. The 246 
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magnitude of the difference between variables of interest were explored using ES thresholds 247 
of trivial (< 0.2), small (> 0.2), moderate (> 0.5), large (> 0.8), and very large (> 1.0) (9). 248 
Changes in HR, SV, 𝑄 ̇ and C(a-v̅)O2 were analysed using mixed model ANOVA. Significant 249 
interactions were followed up using independent samples t-tests. Pearson’s correlation 250 
coefficients assessed relationships between V̇O2 kinetics and mechanistic parameters of O2 251 
delivery and utilization. Statistical analyses were performed using SPSS (version 19.0, SPSS, 252 
Chicago, IL), with the null-hypothesis rejected at alpha level of 0.05.  253 
 254 
RESULTS 255 
Maximal cardiopulmonary exercise testing 256 
Descriptive characteristics and CPET data are presented in Table 2. There were no 257 
differences in body size and composition and lung function between CF and CON. V̇O2max 258 
was reduced in CF compared with CON when normalized using body mass but not FFM.   259 
 260 
Pulmonary ?̇?O2 kinetics  261 
The V̇O2 responses during MOD and VH are presented in Figure 1 and the kinetic parameters 262 
in Table 3. There was no significant difference in baseline V̇O2 between the groups for either 263 
MOD or VH exercise (Table 3). For MOD, CF had no influence on either the phase II τ, TD 264 
or MRT. However, the phase II V̇O2 gain was lower in CF. During VH exercise, the V̇O2 265 
MRT and phase II τ were slower in CF. The phase II TD, amplitude and gain and end-266 
exercise V̇O2 were not altered in CF. A V̇O2 slow-component manifested in all VH responses, 267 
however the amplitude was similar between CF and CON.  268 
 269 
[Insert Table 3 here] 270 
  271 
 272 
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Muscle oxygenation kinetics  273 
The group mean data for [HHb] and the corresponding kinetic parameters are shown in 274 
Figure 2 and Table S1, respectively. The [HHb] response of one CF patient (male, 10 y, 275 
∆F508 homozygote) did not display exponential characteristics and was, in addition to their 276 
healthy control, excluded from [HHb] analyses. There was no difference between CF and 277 
CON for any of the [HHb] kinetic parameters during MOD or VH exercise. 278 
 279 
Heart rate, stroke volume index, cardiac index and C(a-?̅?)O2. 280 
Group mean HR, CI, SVI and C(a-v̅)O2 dynamics are presented in Figure 3. No significant 281 
time by disease state interaction effect for SVI was evident during either MOD (p = 0.09) or 282 
VH (p = 0.27). During VH there was a significant interaction between time and disease state 283 
for HR (p = < 0.01), with follow-up comparisons identifying a higher HR in CF at 30 s (p < 284 
0.05). There was a significant main effect for disease state (p = 0.01) for CI to be lower in CF 285 
during MOD but not VH (p<0.05). There was a time by disease state interaction (p = 0.03) 286 
for C(a-v)O2 during VH (Figure 3d), with extraction significantly reduced in CF at 30 s (p = 287 
0.02) and a trend towards reduced values at 0 s (p=0.07), 60 s (p=0.05) and 120 s (p=0.07). 288 
?̇?/V̇O2 was not different between the groups for either intensity (p>0.05).  289 
 290 
Relationships between ?̇?O2 kinetics and mechanistic parameters 291 
During MOD, the phase II V̇O2 τ significantly correlated with ∆[HHb] (r=0.84; p=0.04) in 292 
CF, whilst the MOD V̇O2 MRT correlated with ∆SVI in CON (r= -0.81; p=0.03). During VH, 293 
the ∆C(a-v̅)O2 significantly correlated with the phase II V̇O2 τ (r= -0.85; p=0.02) and MRT (r= 294 
-0.79; p=0.03) in CF. Furthermore, ∆?̇?/∆V̇O2 (r=0.78; p=0.04) significantly correlated with 295 
the phase II V̇O2 τ in CF during VH exercise.     296 
 297 
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DISCUSSION  298 
This is the first study to examine the dynamics of V̇O2 in children and adolescents with mild-299 
to-moderate CF at the onset of MOD and VH intensity cycling exercise, relative to 300 
adjustments in central O2 delivery and localized muscle (m. vastus lateralis) O2 extraction. 301 
The novel findings from this study are: 1) V̇O2 kinetics were slowed in CF during VH but not 302 
MOD; 2) no differences in muscle [HHb] kinetics were found between CF and CON during 303 
MOD and VH exercise; 3) during VH exercise only, C(a-v̅)O2 was reduced in CF within the 304 
initial 60 s of exercise onset, and 4) the change in C(a-v̅)O2 during VH exercise was 305 
significantly correlated with the phase II V̇O2 τ and MRT in CF. Collectively, these findings 306 
support the notion that impaired muscle oxidative metabolism in young CF patients is 307 
dependent on the intensity of exercise and principally limited by muscular factors, which 308 
limit the extraction and utilisation of O2 during VH exercise  309 
 310 
Contrary to our hypothesis, neither the phase II or overall V̇O2 kinetics were slowed during 311 
MOD intensity cycling in young people with CF. This is consistent with early observations in 312 
similarly aged patients (11.1-15.3 y) with mild airway obstruction during 6 minutes cycling at 313 
1.7 W·kg
-1
 (7). In contrast, two studies have documented slower V̇O2 dynamics during 314 
exercise in patients with CF (22, 19), however methodological issues may explain this 315 
disparity. Kusenbach et al. (22) employed PRBS exercise which fails to isolate phase II of the 316 
V̇O2 response. Although Hebestreit et al. (19) utilised CWR exercise and isolated phase II, 317 
work rate was not prescribed within physiologically defined intensity domains (18). This 318 
meant patients were likely to be exercising across the MOD-severe intensity domains which, 319 
if the intensity was above the GET, would be consistent with our present findings of slowed 320 
V̇O2 kinetics during VH exercise. Hebestreit and colleagues also used semi-supine exercise 321 
(19), which may reduce muscle perfusion
 
and slow V̇O2 dynamics (20). Finally, the 322 
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combination of adult and paediatric patients (10-33 years) could have contributed to slow 323 
V̇O2 kinetics, since slower phase II kinetics were recently documented in adults with more 324 
advanced CF (22 ± 4 years) during submaximal cycling (1). 325 
 326 
An interesting finding in this study was that the influence of CF on oxidative muscle 327 
metabolism appears to be intensity dependent. This is based on the finding that the phase II 328 
V̇O2 τ and MRT were slowed only during VH exercise and the ES was very large (>1.0). This 329 
is of clinical importance, since slower V̇O2 kinetic response will incur a greater O2 deficit and 330 
a greater degree of substrate-level phosphorylation (increased lactic acid and PCr breakdown) 331 
and the accumulation of fatigue-inducing metabolites (e.g., inorganic phosphate and 332 
hydrogen ions), which may impair exercise tolerance especially during VH exercise in young 333 
people with CF. An exercise intensity dependence to the impaired oxidative metabolism in 334 
CF corresponds with earlier observations in adolescent patients during a 90 s high-intensity 335 
exercise challenge performed within a 
31
Phosphorous Magnetic Resonance Spectroscopy 336 
scanner environment, but not shorter duration or less intense exercise (39). This may reflect 337 
the greater physiological challenge to mitochondrial aerobic metabolism elicited by higher 338 
intensities. 339 
 340 
The longer phase II V̇O2 τ of patients with CF (10-33 y; FEV1: 37-98% predicted) has 341 
previously been linked to inadequate O2 delivery, inferred by a significant relationship with 342 
SpO2 (19). In the current study, bulk blood flow, as inferred using the CI (?̇?), was not 343 
profoundly altered during either MOD or VH exercise in CF. Furthermore, V̇O2 kinetics were 344 
not mechanistically linked to the CI and SVI dynamics in this group of patients, despite 345 
previous reports that early signs of cardiac dysfunction may present in paediatric patients 346 
with CF (18, 33). Although CFTR is involved in the regulation of cardiomyocyte contraction 347 
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(35) and gene mutation targeted therapies have been shown to increase SV in adolescents 348 
with CF (34), the current findings indicate that central O2 delivery does not principally limit 349 
V̇O2 kinetics in young CF patients. This is further supported by research demonstrating that 350 
elevating SpO2 through the inspiration of hyperoxic gas does not improve the kinetics of V̇O2 351 
in patients with CF (22). However, it must be acknowledged that only central indices of O2 352 
delivery, which are relatively poor indicators of O2 delivery at the local muscle level during 353 
exercise (24), were obtained in these studies.  354 
 355 
However, considering the findings in the present study, the impaired V̇O2 kinetics during VH 356 
exercise were related to the capacity of skeletal muscle to extract and utilize O2. For the first 357 
time, this study investigated the [HHb] dynamics of young patients with CF during CWR 358 
exercise, with similar kinetics observed between the groups. If muscle O2 availability was 359 
limiting oxidative metabolism in CF, a compensatory acceleration in the rate of O2 extraction 360 
would be expected (16). This was not observed in the present study and this finding 361 
corresponds with earlier studies during incremental exercise using both NIRS (33) and 362 
respiratory mass spectroscopy (29). Whilst this finding shows that the rate of O2 extraction 363 
taking place was not different in CF compared to CON, [HHb] does not reflect the amount of 364 
O2 extraction taking place. This can be physiologically interpreted from the C(a-v̅)O2 365 
parameter.  366 
 367 
Interestingly, we observed a significant reduction in C(a-v̅)O2 in CF during the early stages of 368 
VH exercise (see Figure 3D), which corresponds with the timing of the phase II portion of the 369 
V̇O2 response. Furthermore, ∆C(a-v̅)O2 significantly correlated with the phase II V̇O2 τ and 370 
MRT during VH in CF only. These findings suggest that the amount of muscle O2 extraction 371 
and utilization is impaired in this patient group near the onset of exercise and is 372 
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mechanistically linked to the dynamics of V̇O2. These findings support previous speculations 373 
regarding a peripheral limitation slowing V̇O2 kinetics in patients with CF (19). This O2 374 
extraction and utilization impairment may be explained by structural and functional changes 375 
in skeletal muscle that are evident in CF (39, 12, 23). Although a recent study has provided 376 
conflicting data (40), slower post-exercise PCr recovery kinetics, measured using 377 
31
Phosporous magnetic resonance spectroscopy, suggest impaired muscle oxidative capacity 378 
in both the  m. vastus lateralis and forearm muscle (39, 12). More recently, reduced local 379 
muscle oxidative capacity was inferred from the recovery of m. vastus lateralis O2 380 
consumption following 15 s of electrical stimulation and subsequent repeated transient 381 
arterial occlusions (15). Evidence of CF-specific muscle metabolic abnormalities (lower 382 
adenosine triphosphate concentration ([ATP]) and ATP:PCr at rest and significantly higher 383 
end-exercise pH values) (39) also support the present suggestions regarding a muscular 384 
abnormality in this patient group.   385 
 386 
The cause(s) of an intramuscular impairment in CF are currently unknown, although several 387 
factors have been proposed. Reduced antioxidant capacity, arising from systemic 388 
inflammation and/or oxidative damage, may lower mitochondrial efficiency (39). However, it 389 
may also be a consequence of the CFTR genetic mutation. CFTR is expressed in skeletal 390 
muscle cells (23) and in vitro study of leucocyte mitochondria in patients with CF 391 
demonstrates that properties of complex I of the respiratory chain are significantly altered 392 
(10). Furthermore, absence of CFTR from skeletal muscle has been shown to dysregulate 393 
calcium homeostasis, augment inflammatory or atrophic gene expression signatures and 394 
increase diaphragm weakness (14). Conversely, improving CFTR (dys)function using 395 
Ivacaftor shows potential to improve aerobic exercise function in adolescents with CF (34). 396 
However, the impact of impaired vascular function on the ability of people with CF to deliver 397 
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O2 locally for extraction also requires further investigation given recent evidence that 398 
vascular endothelial (dys)function is associated with a poorer V̇O2max in young people with 399 
CF (28).  400 
 401 
Whilst the present study provides the first robust investigation of the V̇O2 kinetic response in 402 
young CF patients, there are a number of limitations inherent to the employed measurement 403 
techniques. The considerations regarding NIRS exercise measurements in this population 404 
have recently been outlined in greater detail elsewhere (33), however include a restricted, 405 
heterogenous and superficial area of interrogation and possible inter-site variation in [HHb]. 406 
To minimize these limitations, the NIRS device was secured to the same anatomical region of 407 
all participants to eradicate inter-individual regional differences within the m. vastus 408 
lateralis and [HHb] responses were standardized to the total [HHb] amplitude to provide a 409 
physiologic normalisation (6). Although the utilized thoracic impedance device has been 410 
validated in CF patients (27), this technique provides a non-invasive estimate of SV 411 
and   more detailed echocardiography indices of ventricular function, in addition to further 412 
measurements of vascular endothelial function would be insightful. Further, since CFTR is 413 
expressed in human vasculature and vascular endothelial dysfunction has been related to 414 
V̇O2max in young CF patients (28), contribution to altered V̇O2 kinetics warrants further 415 
investigation. Finally, since muscle fibre type composition and recruitment were not 416 
measured herein, discrepancies in fibre type composition and recruitment strategies between 417 
the groups, cannot be excluded.  418 
 419 
These findings help us to further understand how young people with CF respond to the 420 
increased metabolic demand during activities of daily living and fatiguing exercise. Whilst 421 
children and adolescent with mild-to-moderate CF appear to respond in a similar manner to 422 
17 
  
their healthy counterparts during MOD exercise, the slowed V̇O2 kinetics at the onset of 423 
exercise above the GET may well be linked to reduced exercise tolerance, which should be 424 
considered by the exercise practitioner when considering exercise prescription strategies for 425 
this patient group. Promisingly, identifying the rate limiting determinant(s) of pulmonary V̇O2 426 
kinetics in individuals with CF may provide viable targets for intervention.  427 
 428 
To conclude, this study demonstrates that the V̇O2 kinetics of paediatric patients with CF are 429 
slowed during VH but not MOD intensity cycling exercise. Impaired skeletal muscle 430 
oxidative metabolism in this patient group is intensity dependent and appears to be 431 
mechanistically linked to an intrinsic intramuscular impairment which limits O2 extraction 432 
and utilization. Identifying the rate limiting determinant(s) of pulmonary V̇O2 kinetics in 433 
individuals with CF may provide viable targets for intervention in the future.  434 
 435 
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Figure Legends 571 
 572 
Figure 1. Mean V̇O2 profile for cystic fibrosis (○ white circles) versus healthy (● black 573 
circles) children and adolescents during moderate (A, C) and very heavy (B, D) intensity 574 
cycling exercise. Figures C and D provide the normalized to end-exercise so that the 575 
differences in the phase II region of the V̇O2 response can be observed. The vertical dotted 576 
line illustrates the onset of exercise from a 10 W baseline. Data are presented as 5-s averages 577 
 578 
 579 
Figure 2. Mean [HHb] profile for cystic fibrosis (○ white circles) and healthy (● black 580 
circles) young people during moderate (A,C) and very heavy (B,D) intensity cycling exercise. 581 
Figures C and D provide the normalized to end-exercise so that the differences in the phase II 582 
region of the [HHb] response can be observed The vertical dotted line denotes the onset of 583 
exercise from a 10 W baseline. Data are presented as 5-s averages. 584 
 585 
 586 
Figure 3. Group mean heart rate (A), fat-free mass (FFM) normalized stroke volume (B), 587 
FFM normalized cardiac output (C) and FFM normalized arterial-venous O2 content 588 
difference [C(a-v)O2] (D) dynamics of young cystic fibrosis patients (○ white circles) and 589 
healthy age- and gender-matched controls (● black circles) during moderate (1) and very 590 
heavy (2) intensity cycling exercise. The vertical dotted line denotes the onset of exercise 591 
from a 10 W baseline. Data are mean and SD and 30-s averages. * denotes P < 0.05, i.e. 592 
significant mean difference between CF patients and healthy controls, whilst 
+
 denotes a 593 
statistical trend (p = 0.07).  594 
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